Despite the relative success of CD19-directed CAR T-cell therapy in treating B-cell malignancies, only a minority of patients with CAR T cell–treated CLL will be classed as complete responders, highlighting a remaining unmet need for curative therapies. Here, CD19 is linked to B-cell chronic lymphocytic leukemia.